Mizuho Securities Reiterates Buy Rating, $20 PT on eFFECTOR Therapeutics (EFTR) Following CMO Departure, Sees Upcoming Phase IIa zotatifin Data as Key to Pipeline Validation
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $20.00 price target on eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
